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Abstract (word count 247) 
Objectives: The high mortality among HIV/tuberculosis (TB) co-infected patients in Eastern 
Europe (EE) is partly explained by the high prevalence of drug-resistant TB. It remains unclear 
whether outcomes of HIV/TB patients with rifampicin/isoniazid-susceptible TB in EE differ from 
those in Western Europe (WE) or Latin America (LA). 
Methods: One-year mortality of HIV-positive patients with rifampicin/isoniazid-susceptible TB in 
EE, WE and LA was analysed and compared in a prospective observational cohort study. Factors 
associated with death were analysed using Cox regression models  
Results: 341 patients were included (EE 127, WE 165, LA 49). Proportions of patients with 
disseminated TB (50%, 58%, 59%) and initiating rifampicin+isoniazid+pyrazinamide-based 
treatment (93%, 94%, 94%) were similar in EE, WE and LA respectively, while receipt of 
antiretroviral therapy (ART) at baseline and after 12 months was lower in EE (17%, 39%, 39%, and 
69%, 94%, 89%). The one-year probability of death was 16% (95%CI 11%-24%) in EE, vs. 4% 
(2%-9%) in WE and 9% (3%-21%) in LA; p<0.0001. After adjustment for injecting drug use 
(IDU), CD4-cell count and receipt of ART, those residing in EE were at nearly 3-fold increased risk 
of death compared to those in WE/LA (aHR 2.79 (1.15-6.76); p=0.023).  
Conclusions: Despite comparable use of recommended anti-TB treatment, mortality of patients 
with rifampicin/isoniazid-susceptible tuberculosis remained higher in EE when compared with 
WE/LA. The high mortality in EE was only partially explained by IDU, use of ART and  CD4 cell 
count. These results call for improvement of care for TB/HIV patients in EE. 
Key words: tuberculosis, HIV, treatment, drug -susceptibility testing, death, Eastern Europe, 
Western Europe, Latin America, TB:HIV study  
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Introduction 
Currently, tuberculosis (TB) is a public health emergency in Eastern Europe (EE). [1] The incidence 
of TB among HIV-infected populations is rapidly increasing in this region, and the situation is 
complicated by an increase in the prevalence of multi-drug resistant (MDR) TB. [2-4] We have 
previously documented an excess mortality rate among TB/HIV patients in EE, which can only 
partially be explained by the high prevalence of MDR-TB, suboptimal access to drug susceptibility 
testing (DST), and as a consequence, use of inadequate anti-TB treatment regimens. [5]  
One of the risk factors for development of MDR-TB is previous (inadequate) TB treatment which 
permitted drug resistance to be selected or amplified. [6, 7] By contrast, high rates of MDR-TB 
among new TB cases without a history of prior TB, as well data from modelling studies, suggest 
that transmission of drug resistant TB plays an important role in the ongoing epidemic of MDR-TB 
in EE. [8, 9] From a patient as well as from a public health perspective it is therefore important to 
appropriately treat drug sensitive (DS) TB, ensuring that patients are cured and their infection is 
eliminated. This strategy would help prevent the development and potential further spread of MDR-
TB.  Treatment of MDR-TB is complex due to the drug burden, prolonged treatment duration, 
adverse effects, high cost, and the limited availability of many drugs in low- and middle-income 
regions. [10-12] Besides, the overall success rate of treating MDR-TB is only around 50%. [13] By 
contrast, treatment of drug susceptible (DS)-TB is inexpensive, requires fewer clinical (nurse- and 
doctor-led) resources, and first-line drugs are widely available in resource-limited settings. [14, 15] 
Provided that recommendations for treatment of DS-TB are used and adhered to both by clinicians 
and patients, successful TB outcome can be achieved in a majority of patients, which is according to 
World Health Organisation (WHO) 2015 standards. [16]  
In the presence of HIV coinfection, it is also of paramount importance to adequately treat the 
underlying HIV infection. [17] Timely initiation of antiretroviral therapy (ART) improves immune 
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function and hence prevents of active TB disease, or in the settings of already developed TB, 
significantly improves outcome. [18, 19] 
We hypothesised that mortality rates among TB/HIV patients with DS-TB in EE would be 
comparable to those in Western Europe (WE) and Latin America (LA). The present analysis aimed 
to assess and compare mortality rates of HIV patients with drug susceptible TB across regions and 
identify risk factors associated with mortality. Further, we aimed to describe management of HIV 
co-infection in patients with DS-TB. 
Methods 
The current analyses were conducted within the prospective TB:HIV cohort study. Details of the 
study design and methodology have been published elsewhere. [20] Briefly, HIV-positive persons 
aged 16 years or older who were diagnosed with TB between January 2011 and December 2013 in 
62 participating HIV and TB clinics in 19 countries from EE, WE or LA 1 were enrolled and 
followed-up for 24 months. Demographic, clinical and laboratory information was prospectively 
collected on case report forms at TB diagnosis, 6, 12 and 24 months thereafter. The study received 
approval from Ethics Committees in all countries as per local regulations. 
The current analysis is limited to 12 months of follow-up and the database was closed for analysis 
in May 2015, when all 12 months follow-up data were collected. Baseline was defined as the date 
when anti/TB treatment was initiated. Drug susceptibility tests (DST), obtained within 4 weeks of 
baseline were used to confirm mycobacterial susceptibility to rifampicin and isoniazid. Patients 
without a DST and those with rifampicin- and/or isoniazid-resistant TB were excluded from the 
current analyses. Patients were stratified by their region of residence. Descriptive statistics were 
                                                            
1 Eastern Europe (EE) (21 clinics in Belarus, Estonia, Georgia, Latvia, Lithuania, Poland, Romania, Ukraine, Russia), 
Western Europe (WE) (28 clinics in Belgium, Denmark, France, Italy, Spain, Switzerland, United Kingdom), and Latin 
America (LA) (13 clinics in Argentina, Chile, and Mexico). 
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used for baseline characteristics. Study definitions in terms of certainty of TB diagnosis, clinical 
presentation of TB disease, TB treatment regimens, ART regimens and region of residence have 
previously been published and re-used in the current analysis for consistency. [5] 
Treatment of underlying HIV-infection was analysed by calculating proportion of patients receiving 
antiretroviral therapy (ART) at baseline, 3, 6, 9 and 12 months, and by assessing immuno-
virological status of the cohort at the same time-points. Response to ART was assessed among 
those who started ART at or within 6 months after their TB diagnosis. It was done by calculating 
proportion of patients with HIV-RNA <500 copies/ml in the time period 2-7 months after starting 
ART out of those alive and still under follow-up. ART was defined as a combination of at least 
three antiretroviral drugs of any class. 
Mortality was compared using Kaplan-Meier survival analysis in which patients were censored at 
their last clinic visit, date of death, or after 12 months of follow-up, whichever occurred first. Risk 
factors for death were identified by Cox proportional hazard models that included region of 
residence, where WE and LA were combined due to the small numbers of deaths in these regions.  
Following “a priori” defined variables were tested in the uni- and multivariate models:  gender, age 
(per 10 years increase), history of injection drug use (IDU: yes or no), extent of TB disease 
(pulmonary or disseminated), use of rifampicin, isoniazid and pyrazinamide in the initial anti-TB 
treatment regimen, baseline CD4 cell count (as a categorical variable), and use of ART (yes/no) as a 
time-updated variable. 
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Results 
Of the 1406 TB/HIV patients in the TB:HIV study, 644 (46%) had culture confirmed TB (360 of 
834 enrolled participants in EE, 205 of 317 in WE, and 79 of 255 in LA, respectively). Of the 644 
patients, 495(77%) had baseline DST results for both rifampicin and isoniazid available, and finally 
341/495 (69%) were infected with Mycobacterium tuberculosis susceptible to both rifampicin and 
isoniazid. The regional distribution was EE 127, WE 165, and LA 49. These 341 patients were 
included in the present analyses (figure 1). 
The baseline clinical and demographic characteristics of these patients are described in table 1. 
Compared with WE and LA, patients in EE were slightly younger and a greater proportion in this 
region was co-infected with hepatitis C. The most common risk factors for TB/HIV acquisition in 
EE were: history of IDU, excess alcohol consumption, and/or imprisonment.  The proportion of 
patients with excess alcohol consumption was comparably high in LA, but not in WE. More than 
90% of patients in all three regions commenced anti-TB treatment that included rifampicin, 
isoniazid, and pyrazinamide.  At the time of TB diagnosis, patients from all regions had advanced 
immunodeficiency and over half presented with disseminated TB. Despite similar degrees of 
immunodeficiency and HIV RNA levels, a smaller proportion of those in EE were receiving ART at 
baseline. 
In Kaplan-Meier analyses of the duration of TB therapy, the time by which 50% of patients had 
stopped therapy was longer than the guideline-recommended six months in all 3 regions: 8.7 
months (IQR 7.1-9.7) in EE, 9.0 (8.3-9.1) in WE and 9.8 (9.0-11.5) in LA. There was no evidence 
that the time to stopping TB treatment differed between regions (p=0.28). 
Management of HIV infection after initiation of anti-TB treatment is presented in figure 2. The use 
of ART increased over time in all three regions, but remained significantly lower in EE. The 
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
proportion of patients receiving ART in Eastern Europe increased from 17% to 54% during the first 
three months after start of anti-TB treatment. Proportion of patients on ART in the two other 
regions was significantly higher at any time point and at 12 months 94% and 89% of patients in WE 
and LA respectively, were on ART compared with 69% in EE, p<0.001(figure 2). Despite the 
increase in ART uptake, the proportion of patients with suppressed HIV-RNA (<500 copies/ml), 
among those who were on ART, was lower in EE compared with WE and LA. At 12 months after 
TB diagnosis, 48% of patients on ART in EE had HIV RNA<500 compared with 86% and 71% in 
WE and LA, respectively, p<0.001(figure 2). 
In addition to describing ART use, HIV RNA and CD4-cell status cross-sectionally at time-points 
after TB diagnosis (Figure 2), we also looked at the response to ART following the date of ART 
initiation among those who started ART at or after TB diagnosis. This analysis showed that in the 
time period 3-6 months after starting ART, 36% of individuals still alive and under follow-up in EE 
compared to 85% in WE and 80% in LA had HIV RNA<500 copies/ml (p<0.001). 
At one year from baseline, 68 patients (54%) in EE, 117 (71%) in WE and 30 (61%) in LA had 
completed at least 6 consecutive months of anti-TB treatment, p=0.009. Seventeen patients (13%) 
in EE, 17 (10%) in WE, and 7 (14%) in LA were lost to follow up, p=0.63. Twenty (16%) deaths 
had occurred in EE, 7 (4%) in WE and 4 (8%) in LA, p=0.0031. In EE TB was indicated as the 
underlying cause of death in 13 (70%) cases, compared with 2 (29%) and 1 (25%) in WE and LA, 
respectively. A majority (9 out of 13) of TB-related death in EE occurred within the first 4 months 
after baseline. The cumulative probability of all cause death after one year was 16% (95% CI 11%-
24%) in EE, 4% (2%-9%) in WE and 9% (3%-21%) in LA (figure 3), and numbers did not allow 
for more detailed analysis on intra-regional variability. In the adjusted model the only significant 
risk factor for death was region of residence. Thus, treatment of rifampicin and isoniazid susceptible 
TB in EE was associated with an almost 3-fold increased risk of death compared to WE and LA 
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combined (adjusted Hazard Ratio 2.79; 95% CI 1.15-6.76) (figure 4). Association of ART initiation 
with patients’ prognosis was marginally significant in the unadjusted model only. This association 
disappeared after adjustment likely due to the small numbers and limited statistical power. IDU was 
also a significant predictor of death before adjustment, however this also became non-significant 
after adjustment due to the high correlation with the region of residence (figure 4). 
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Discussion 
This study demonstrates greater mortality rate among HIV patients infected with rifampicin-and 
isoniazid-susceptible TB in EE compared with WE and LA. This difference persisted after 
adjustment for clinical characteristics such as IDU, low immune status at the time of TB diagnosis, 
and receipt of ART during follow up. While mortality was similar across the regions within the first 
1-2 months, patients in EE continued to experience high death rates throughout the first year post-
TB diagnosis.  By contrast with EE, TB/HIV coinfected patients in LA, another middle-income 
region, and in WE, a high income region, experienced low mortality rates, reflecting high standards 
of TB and HIV care in the latter mentioned regions. [17, 21, 22] The differences in TB outcome 
were only partially explained by factors, related to HIV management, in particular use of ART and 
CD4 cell levels, or by other factors included in the model.  This underscores the fact that some other 
factors, probably on a higher level than individual clinics and that we were not able to test, play an 
important role in patients’ survival, as for example:  national and regional healthcare and social 
infrastructure. 
A vast majority of patients from all regions initiated their anti-TB treatment with the standard 
recommended regimen, i.e. rifampicin, isoniazid, and pyrazinamide-based, indicating that these 
drugs are widely available and clinicians follow standard recommendations for TB treatment. [14]  
This is however not enough to ensure a good outcome, particularly in the settings of HIV 
coinfection. ART should be initiated as soon as possible after TB diagnosis, if a patient was not 
already receiving it. [23-25] In our study, management of HIV infection in EE was suboptimal. 
Even though ART coverage had increased with time, both usage of ART and response to ART was 
still much lower than in the other regions, inferring that ART was not properly prescribed and/or 
taken. By contrast, HIV management in WE was according to the standards; ART coverage was 
over 90% and nearly 90% of patients on ART achieved viral suppression. [26] LA showed results 
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very close to those in WE, demonstrating that appropriate HIV care is also possible in resource-
constrained settings. In our study, initiation of ART did not play a significant role in patients’ 
survival after adjustment for other risk factors for death. However, binary adjustment for ART 
initiation (yes vs. no) may not fully reflect the impact of ART on mortality, and there are other 
aspects of HIV treatment that we could not adjust for due to the lack of data, and therefore not fully 
capture all aspects of HIV care. Scale up of ART still remains paramount in the management of 
HIV infection, although it is also important to ensure that effective drugs are used and that 
adherence is maximised. In the present study the most common reason for not starting ART by two 
months after start of anti-TB treatment was patients’ refusal (data not shown), suggesting perhaps 
that patients may not fully appreciate or are not aware of the life-saving effects of ART. Other 
factors, as for example, concerns of toxicity, lack of food and/or accommodation might also play a 
role and need to be overcome.  It is therefore a major task not only for clinicians, but also for 
community and social services to educate, engage and retain patients in care. 
One of the drivers of the TB/HIV epidemic in EE is IDU, a marginalised population with poor 
access to and uptake of health services, resulting in late presentation of both HIV and TB, poor rates 
of TB treatment completion, and frequent ART interruptions.  [27] Healthcare systems in EE need 
to better account the special needs of this large patient population, considering its lifestyle and 
ability to accept continuous treatment. [27] Measures should be taken to help IDU patients to 
remain in care and overcome structural barriers, improve health literacy and minimise stigma. There 
is a need for a patient-centred integrated multidisciplinary approach, involving both HIV and TB 
clinicians, as well as social support and provision of opiate substitution therapy, which is currently 
poorly available. [28-31] Integration of HIV and TB services, although improving, is still 
suboptimal in EE and close collaboration of physicians from both specialities is limited. Healthcare 
infrastructure continues to be driven by a strong vertical system, not allowing for interdisciplinary 
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collaboration. [12]  Community involvement and patients’ education and support services need to 
be improved as well.  
 Of note, we were not able to document any significant differences in mortality within EE in 
explorative analyses stratified by IDU status (yes vs. no), perhaps due to limited numbers, but it 
may also be due to high prevalence of risk factors such as alcohol abuse and imprisonment among 
non-IDU individuals. This highlights the need for an approach that supports vulnerable patient 
groups in addition to individuals who are IDU. Prevalence of HCV coinfection is rather high among 
HIV/TB patients in EE (app. 50% in our study), thus management of this disease should also be 
integrated. 
The study has several strengths and limitations. As a prospective cohort study, our data reflect the 
“real life” situation in the participating clinics/countries in terms of data availability, such as DST, 
HIV-RNA, CD4 cell count, at the same time limiting interventions and more careful study of the 
risk factors, associated with death.  Many clinics in EE do not have the infrastructure to support 
patients’ retention in care. Moreover, patients may have to attend different facilities for inpatient 
and outpatient treatment. Thus the loss to follow-up rate might be high, although major attempts 
have been taken to minimise it. All missing data were queried, all death, MDR-TB cases and at least 
10% of random patients were monitored and guidelines on how to minimise LTFU was developed 
(www.cphiv.dk).  The study did not collect detailed data on issues of special relevance for IDU 
individuals, such as adherence and whether there is an ongoing IDU and how that influences the 
patients’ life.  Due to the limited statistical power, risk factors of death could not be studied in more 
detail. The fact that the multivariate model did not remove the difference between regions does not 
exclude the possibility that the variables adjusted for in this model were on the causal pathway. 
There might be an issue of residual confounding, where the quality and availability of the variables 
(e.g. HIV-related) is insufficient to capture the biological changes that truly occurred. End-stage 
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liver disease due to HCV coinfection might have contributed to the excess mortality in EE. 
However, we were not able to explore this further due to the statistical power limitations. Detailed 
analysis of causes of death and contributing factors is currently under development. Finally, there 
may be a general lower life expectancy in EE due to differences in socio-economic status, lifestyle, 
diets etc. This is, however, difficult to address in a clinical study and further research is needed. 
 
 
 
Conclusion 
In conclusion, this study documents an unacceptable high mortality among HIV-positive patients 
with drug-susceptible TB in EE despite widespread use of World Health Organization 
recommended anti-TB treatment regimens as initial therapy. Management of HIV infection was 
suboptimal in this region, but did not fully explain the high mortality. Healthcare provision for the 
TB/HIV population in EE needs to be urgently reviewed and improved. This requires a high level of 
political commitment both locally and globally, and may be achieved by improving collaboration 
between TB and HIV clinicians, as well as strengthening the existing healthcare infrastructure.   
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Table 1. Baseline demographic and clinical characteristics of 341 HIV patients with rifampicin- and isoniazid-susceptible tuberculosis 
    Eastern Europe 
N(%) 
Western Europe N(%) Latin America N(%) P 
Total   127 165 49  
Gender Male 98 (77.2) 109 (66.1) 36 (73.5) 0.108 
Age Years, Median (IQR) 36.5 (30.9 - 42.6) 38.8 (33.0 - 46.2) 38.2 (29.2 - 44.8) 0.037 
Weight Kg, Median (IQR) 58.0 (50.0 - 66.0) 60.0 (54.0 - 68.0) 55.0 (45.5 - 65.5) 0.225 
TB/HIV Risk Factors Ever Injecting drug use, N 
(%) 
76 (60.3) 31 (18.8) 8 (16.3) <.001 
  History of imprisonment, N 
(%) 
16 (12.6) 5 (3.0) 4 (8.2) 0.008 
  History of excess alcohol 
consumption, N (%) 
27 (21.3) 20 (12.1) 13 (26.5) 0.026 
Laboratory Markers Haemoglobin (g/dl), 
median (IQR)* 
11 (9 - 13) 11 (9 - 12) 11 (10 - 13) 0.158 
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  Albumin (g/dl), median 
(IQR)# 
29 (24 - 33) 30 (25 - 34) 26 (22 - 33) 0.484 
 TB Disease Disseminated, N (%) 64 (50.4) 95 (57.6) 29 (59.2) 0.39 
TB Treatment RHZ-based, N (%) 118 (92.9) 155 (93.9) 46 (93.9) 0.935 
   RHZ+E, N (%) 98 (83.1) 128 (82.6) 43 (93.5) 0.181 
   RHZ+S, N (%) 1 (0.8)   0.426 
   RHZ+ES, N (%) 10 (8.5) 3 (1.9) 1 (2.2) 0.024 
Hepatitis C@ Ever, N (%) 61 (48.0) 27 (16.4) 6 (12.2) <0.001 
HIV Status      
Antiretroviral 
therapy 
Yes. N (%) 21 (16.5) 64 (38.8) 19 (38.8) <0.001  
CD4 cell count, 
mm3/ml1 
Median (IQR) 103.5 (35.0 - 258.0) 123.0 (35.0 - 280.0) 78.0 (28.0 - 218.0) 0.31 
HIV RNA, log10 
copies/ml2 
Median (IQR) 
5.2 (4.3 - 5.7) 5.0 (2.9 - 5.7) 4.7 (2.5 - 5.6) 0.289 
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Eastern Europe (Belarus, Estonia, Georgia, Latvia, Lithuania, Poland, Romania, Ukraine, Russia); Western  Europe (Belgium, Denmark, France, Italy, 
Spain, Switzerland, United Kingdom); Latin America (Argentina, Chile, and Mexico) 
*Data for haemoglobin available for 98 (77) patients in EE, 146 (88) in WE, and 41 (84) in LA 
#Data for albumin available for 38 (30) patients in EE, 113 (68) in WE, and 26 (53) in LA 
@Ever tested positive for hepatitis C antibodies or hepatitis C RNA. Data for hepatitis C available for 91 (72) patients in EE, 121 (73) in WE, and 36 
(73) in LA. Missing data are included in the denominator.  
1Baseline CD4 cell count was available for 102 (80), 162 (98) and 43 (88) patients in EE, WE, and LA 
2Baseline HIV RNA data were available for 68 (54), 157 (95) and 40 (82) patients in EE, WE, and LA 
R = Rifampicin; H = Isoniazid; Z = Pyrazinamide; E = Ethambutol; S = Streptomycin  
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 Figure 2: Use of antiretroviral therapy (ART), HIV-RNA and CD4-cell count status in 341 HIV-patients with drug-susceptible tuberculosis 
during 12 months after initiation of anti-TB therapy 
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Figure 4. Cox proportional hazard model of factors associated with death in 341 HIV 
patients with rifampicin- and isoniazid-susceptible tuberculosis 
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*ART was included as a time updated variable 
 
 
Number of deaths = 31: 20 in Eastern Europe, 7 in Western Europe and 4 in Latin America. 
Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
   
EE: Eastern Europe (Belarus, Estonia, Georgia, Latvia, Lithuania, Poland, Romania, Ukraine, 
Russia); WE: Western Europe (Belgium, Denmark, France, Italy, Spain, Switzerland, United 
Kingdom); LA: Latin America (Argentina, Chile, and Mexico) 
IDU, injecting drug use; ART, antiretroviral therapy; CD4 cell count measurement (cells/mm3) 
HR, hazard ratio; CI, confidence interval;  
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